Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1959 Oct;38(10 Pt 1-2):1746–1755. doi: 10.1172/JCI103953

THE REMOVAL OF LIPOPROTEIN LIPASE FROM THE BLOOD BY THE NORMAL AND DISEASED LIVER*,†

William E Connor 1,‡, John W Eckstein 1
PMCID: PMC444142  PMID: 13811564

Full text

PDF
1746

Images in this article

1750Image
on p.1750
1750Image
on p.1750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANGERVALL G., HOOD B. Studies on heparin and lipemia clearing factor; inhibition towards clearing in plasma from normal and atherosclerotic individuals. Acta Med Scand. 1957 Jun 5;157(5):407–415. [PubMed] [Google Scholar]
  2. Anfinsen C. B., Boyle E., Brown R. K. The Role of Heparin in Lipoprotein Metabolism. Science. 1952 May 30;115(2996):583–586. doi: 10.1126/science.115.2996.583. [DOI] [PubMed] [Google Scholar]
  3. BAKER S. P. Heparin-activated clearing factor; standardized test, agewise application, and clinical observations. Circulation. 1957 Jun;15(6):889–896. doi: 10.1161/01.cir.15.6.889. [DOI] [PubMed] [Google Scholar]
  4. BAKER S. P., LEVINE H., TURNER L., DUBIN A. Lipoprotein lipase response in Laennec's cirrhosis. Proc Soc Exp Biol Med. 1958 Dec;99(3):670–672. doi: 10.3181/00379727-99-24458. [DOI] [PubMed] [Google Scholar]
  5. BLOCK W. J., Jr, MANN F. D., BARKER N. W. Effect of small doses of heparin in increasing the translucence of plasma during alimentary lipemia; studies in normal individuals and patients with atherosclerosis. Proc Staff Meet Mayo Clin. 1951 Jun 20;26(13):246–249. [PubMed] [Google Scholar]
  6. Bradley S. E., Ingelfinger F. J., Bradley G. P., Curry J. J. THE ESTIMATION OF HEPATIC BLOOD FLOW IN MAN. J Clin Invest. 1945 Nov;24(6):890–897. doi: 10.1172/JCI101676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. CHO M. H., JAQUES L. B. Heparinase. III. Preparation and properties of the enzyme. Can J Biochem Physiol. 1956 Jul;34(4):799–813. [PubMed] [Google Scholar]
  8. CONSTANTINIDES P., SO Y., JOHNSTONE F. R. Role of liver and kidney in development of heparin-induced lipemia clearing activity. Proc Soc Exp Biol Med. 1959 Feb;100(2):262–264. doi: 10.3181/00379727-100-24593. [DOI] [PubMed] [Google Scholar]
  9. CREED D. L., BAIRD W. F., FISHER E. R. The severity of aortic arteriosclerosis in certain diseases; a necropsy study. Am J Med Sci. 1955 Oct;230(4):385–391. doi: 10.1097/00000441-195510000-00004. [DOI] [PubMed] [Google Scholar]
  10. DAY A. J., WILKINSON G. N. Clearing factor inhibitor in human atherosclerosis. Circulation. 1958 Jul;18(1):76–81. doi: 10.1161/01.cir.18.1.76. [DOI] [PubMed] [Google Scholar]
  11. DOLE V. P. A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J Clin Invest. 1956 Feb;35(2):150–154. doi: 10.1172/JCI103259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. EIBER H. B., DANISHEFSKY I. Synthesis and metabolism of radioactive heparin. AMA Arch Intern Med. 1958 Aug;102(2):189–193. doi: 10.1001/archinte.1958.00260200017003. [DOI] [PubMed] [Google Scholar]
  13. ENGELBERG H. Studies indicating inactivation of post-heparin and endogenous human plasma lipoprotein lipase during triglyceride lipolysis. Proc Soc Exp Biol Med. 1958 Nov;99(2):489–493. doi: 10.3181/00379727-99-24394. [DOI] [PubMed] [Google Scholar]
  14. GORDON R. S., Jr, CHERKES A. Unesterified fatty acid in human blood plasma. J Clin Invest. 1956 Feb;35(2):206–212. doi: 10.1172/JCI103265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. GROSSMAN M. I. The quantitative measurement of heparin-induced lipemia clearing activity of plasma. J Lab Clin Med. 1954 Mar;43(3):445–451. [PubMed] [Google Scholar]
  16. HALL E. M., OLSEN A. Y., DAVIS F. E. Portal cirrhosis; clinical and pathologic review of 782 cases from 16,600 necropsies. Am J Pathol. 1953 Nov-Dec;29(6):993–1027. [PMC free article] [PubMed] [Google Scholar]
  17. Hahn P. F. ABOLISHMENT OF ALIMENTARY LIPEMIA FOLLOWING INJECTION OF HEPARIN. Science. 1943 Jul 2;98(2531):19–20. doi: 10.1126/science.98.2531.19. [DOI] [PubMed] [Google Scholar]
  18. JEFFRIES G. H. The sites at which plasma clearing activity is produced and destroyed in the rat. Q J Exp Physiol Cogn Med Sci. 1954;39(4):261–270. doi: 10.1113/expphysiol.1954.sp001080. [DOI] [PubMed] [Google Scholar]
  19. KLEIN E., LEVER W. F., FEKETE L. L. Inhibitors of lipemia clearing in tissues. J Invest Dermatol. 1958 Feb;30(2):41–42. [PubMed] [Google Scholar]
  20. KORN E. D. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem. 1955 Jul;215(1):1–14. [PubMed] [Google Scholar]
  21. KORN E. D. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem. 1955 Jul;215(1):15–26. [PubMed] [Google Scholar]
  22. KORN E. D. Inactivation of lipoprotein lipase by heparinase. J Biol Chem. 1957 Jun;226(2):827–832. [PubMed] [Google Scholar]
  23. KORN E. D., QUIGLEY T. W., Jr Lipoprotein lipase of chicken adipose tissue. J Biol Chem. 1957 Jun;226(2):833–839. [PubMed] [Google Scholar]
  24. LABECKI T. D. Hyperchylomicronemia and hypercholesterolemia: their correlation with clinical atherosclerosis. Am J Clin Nutr. 1955 Mar-Apr;3(2):132–140. doi: 10.1093/ajcn/3.2.132. [DOI] [PubMed] [Google Scholar]
  25. LEDUC E. H., WILSON J. W. Injury to liver cells in carbon tetrachloride poisoning; histochemical changes induced by carbon tetrachloride in mouse liver protected by sulfaguanidine. AMA Arch Pathol. 1958 Feb;65(2):147–157. [PubMed] [Google Scholar]
  26. MACDONALD R. A., MALLORY G. K. The natural history of postnecrotic cirrhosis; a study of 221 autopsy cases. Am J Med. 1958 Mar;24(3):334–357. doi: 10.1016/0002-9343(58)90321-8. [DOI] [PubMed] [Google Scholar]
  27. MORRIS B., FRENCH J. E. The uptake and metabolism of 14C labelled chylomicron fat by the isolated perfused liver of the rat. Q J Exp Physiol Cogn Med Sci. 1958 Apr;43(2):180–188. doi: 10.1113/expphysiol.1958.sp001315. [DOI] [PubMed] [Google Scholar]
  28. Moreton J. R. Atherosclerosis and Alimentary Hyperlipemia. Science. 1947 Aug 29;106(2748):190–191. doi: 10.1126/science.106.2748.190. [DOI] [PubMed] [Google Scholar]
  29. PILGERAM L. O. Deficiencies in the lipoprotein lipase system in atherosclerosis. J Gerontol. 1958 Jan;13(1):32–42. doi: 10.1093/geronj/13.1.32. [DOI] [PubMed] [Google Scholar]
  30. ROBINSON D. S. Further studies on the lipolytic system induced in plasma by heparin injection. Q J Exp Physiol Cogn Med Sci. 1956 Apr;41(2):195–204. doi: 10.1113/expphysiol.1956.sp001175. [DOI] [PubMed] [Google Scholar]
  31. ROBINSON D. S., HARRIS P. M. The production of lipolytic activity in the circulation of the hind limb in response to heparin. Q J Exp Physiol Cogn Med Sci. 1959 Jan;44(1):80–90. doi: 10.1113/expphysiol.1959.sp001378. [DOI] [PubMed] [Google Scholar]
  32. SHORE B., NICHOLS A. V., FREEMAN N. K. Evidence for lipolytic action by human plasma obtained after intravenous administration of heparin. Proc Soc Exp Biol Med. 1953 Jun;83(2):216–220. doi: 10.3181/00379727-83-20312. [DOI] [PubMed] [Google Scholar]
  33. SPITZER J. A., SPITZER J. J. Effect of liver on lipolysis by normal and post-heparin sera in the rat. Am J Physiol. 1956 Apr;185(1):18–22. doi: 10.1152/ajplegacy.1956.185.1.18. [DOI] [PubMed] [Google Scholar]
  34. WOLDOW A., CHAPMAN J. E., EVANS J. M. Fat tolerance in subjects with atherosclerosis: heparin effects upon lipemia, lipoproteins, and gamma globulin. Am Heart J. 1954 Apr;47(4):568–579. doi: 10.1016/0002-8703(54)90237-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES